Compared to individuals without APOE4, AD patients with APOE4 exhibit significantly reduced expression of Aβ-degrading enzymes, such as neprilysin and IDE, resulting in diminished Aβ degradation capacity [92]. The gene discussed is APOE; the disease is Alzheimer disease.